4.6 Article

Neuropathologically mixed Alzheimer's and Lewy body disease: burden of pathological protein aggregates differs between clinical phenotypes

Journal

ACTA NEUROPATHOLOGICA
Volume 129, Issue 5, Pages 729-748

Publisher

SPRINGER
DOI: 10.1007/s00401-015-1406-3

Keywords

Alzheimer's disease; Lewy body disease; Mixed dementia; Quantitative neuropathology

Funding

  1. National Institute for Health Research (NIHR) Biomedical Research Centre for Ageing and Age-related disease
  2. Biomedical Research Unit for Lewy body dementia based at Newcastle upon Tyne Hospital NHS Foundation Trust [R:CH/ML/0712]
  3. Biomedical Research Unit for Lewy body dementia based at Newcastle upon Tyne Hospital Newcastle University [R:CH/ML/0712]
  4. NIHR
  5. Department of Health
  6. UK Medical Research Council [G0400074]
  7. Alzheimer's Society
  8. Alzheimer's Research UK
  9. MRC [G0400074, G0502157, G0900652, MR/L016451/1] Funding Source: UKRI
  10. Alzheimers Research UK [ART-EG2010A-1] Funding Source: researchfish
  11. Alzheimer's Society [199] Funding Source: researchfish
  12. Medical Research Council [G0400074, G0502157, G0900652, MR/L016451/1] Funding Source: researchfish

Ask authors/readers for more resources

Multiple different pathological protein aggregates are frequently seen in human postmortem brains and hence mixed pathology is common. Mixed dementia on the other hand is less frequent and neuropathologically should only be diagnosed if criteria for more than one full blown disease are met. We quantitatively measured the amount of hyperphosphorylated microtubule associated tau (HP-tau), amyloid-beta protein (A beta) and alpha-synuclein (alpha-syn) in cases that were neuropathologically diagnosed as mixed Alzheimer's disease (AD) and neocortical Lewy body disease (LBD) but clinically presented either as dementia due to AD or LBD, the latter including dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD). Our study group consisted of 28 cases (mean age, 76.11 SE: +/- 1.29 years; m:f, 17:11) of which 19 were neuropathologically diagnosed as mixed AD/DLB. Clinically, 8 mixed AD/DLB cases were diagnosed as AD (cAD), 8 as DLB (cDLB) and 3 as PDD (cPDD). In addition, we investigated cases that were both clinically and neuropathologically diagnosed as either AD (pure AD; n = 5) or DLB/neocortical LBD (pure DLB; n = 4). Sections from neocortical, limbic and subcortical areas were stained with antibodies against HP-tau, A beta and alpha-syn. The area covered by immunopositivity was measured using image analysis. cAD cases had higher HP-tau loads than both cDLB and cPDD and the distribution of HP-tau in cAD was similar to the one observed in pure AD whilst cDLB showed comparatively less hippocampal HP-tau load. cPDD cases showed lower HP-tau and A beta loads and higher alpha-syn loads. Here, we show that in neuropathologically mixed AD/DLB cases both the amount and the topographical distribution of pathological protein aggregates differed between distinct clinical phenotypes. Large-scale clinicopathological correlative studies using a quantitative methodology are warranted to further elucidate the neuropathological correlate of clinical symptoms in cases with mixed pathology.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available